接受CAR-T细胞的T细胞淋巴瘤:评估风险和因果关系
Jingqiong Hu1, Cynthia E Dunbar2
1Department of Cell Therapy, Stem Cell Center, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Blood
|October 11, 2024
概括
化学抗原受体T细胞 (CAR-T) 治疗后的二次T细胞淋巴瘤非常罕见. 目前的证据表明,来自CAR载体的插入性突变发生不太可能是这些罕见的二次癌症的主要原因.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 遗传学 遗传学 是一个
背景情况:
- 最近的FDA报告引起了人们对B细胞恶性瘤的CAR-T治疗后的二次T细胞淋巴瘤的担忧.
- 最初的数据对CAR载体插入在瘤发生中的作用缺乏明确性.
研究的目的:
- 审查CAR-T治疗后对二次T细胞淋巴瘤的现有证据.
- 评估CAR载体插入性突变发生在瘤发生中的潜在作用.
- 讨论二次血液性恶性瘤的其他风险因素.
主要方法:
- 报告病例的临床和分子数据的审查.
- 流行病学数据和长期CAR-T接受者队列研究的分析.
- 检查了关于插入瘤发生和艾滋病毒感染的先前研究.
主要成果:
- 很少有病例显示CAR载体插入瘤细胞,但因果关系未被证明.
- 许多报告的病例在瘤细胞中缺乏可检测的载体DNA.
- 流行病学研究和队列数据表明,CAR-T后T细胞淋巴瘤的风险极低.
结论:
- 在CAR-T治疗后T细胞淋巴瘤的风险非常低.
- 通过CAR载体的插入性突变发生不太可能是二次恶性瘤的主要驱动因素.
- 免疫功能障碍和克隆性血液形成可能是更重要的易感因素.
更多相关视频
12:16A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
14.7K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
相关概念视频
01:40Cell-mediated Immune Responses
67.5K
Overview
67.5K
01:27Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488